DOI: http://dx.doi.org/10.18203/2394-6040.ijcmph20214276

A study on adverse events following ChAdOx1 nCoV-19 CovishieldTM vaccination among beneficiaries at tertiary care centre, Hyderabad, India

Sunil Pal Singh Chajhlana, Anjaiah Kanusali, Guru Prasad Manderwad, Vineesh Allenki, Shashidhar Kamineni

Abstract


Background: COVID-19 vaccine in present pandemic situation has been emerged as a blessing in disguise. Studies found to be associated with vaccine side-effects and it is an important factor that influences the confidence of vaccine uptake in general population. Present study was designed to provide an independent evidence on ChAdOx1 nCoV-19 vaccine side effects.

Methods: A cross sectional study was conducted between January 2021 and February 2021 at our tertiary care centre among health care workers vaccinated using a validated questionnaire. Study subjects were contacted through phone to know about any adverse events following immunization for 0-24 hours, 24-48 hours and 48-72 hours. Data collected was entered and analysed with MS excel software 2007 and Epi info 3.5.3.

Results: Healthcare workers participated were 1364. Majority of the symptoms following immunization were highest in age group of 18-28 years. Reported symptoms were pain at the site of injection- 619 (45.4%), fever- 423 (31%), Body pains- 318 (23.3%), headache- 189 (13.9%), tiredness- 142 (10.4%), swelling at the site of injection- 40 (2.9%), dizziness- 30 (2.2%), redness at the site of injection- 25 (1.8%), joint pains- 23 (1.7%), rash- 06 (0.4%), Breathlessness- 03 (0.2%) respectively.

Conclusions: Overall results found the occurrence of side-effects which are in terms of manufacturer’s data and it has been noticed in young age. This study imparts the confidence for taking vaccination and further studies are required to minimize vaccine hesitancy (VH) and strengthen the public to boost their confidence in present vaccination drive.


Keywords


Adverse events following immunization, ChAdOx1 nCoV-19, COVID-19, Vaccination, Vaccine hesitancy

Full Text:

PDF

References


Dror AA, Eisenbach N, Taiber S, Morozov NG, Mizrachi M, Zigron A, et al. Vaccine hesitancy: the next challenge in the fight against COVID-19. Eur J Epidemiol. 2020;35(8):775-9.

Lucia VC, Kelekar A, Afonso NM. COVID-19 vaccine hesitancy among medical students. J Public Health. 2021;43(3):445-9.

Riad A, Klugar M, Krsek M. COVID-19-related oral manifestations: early disease features? Oral Dis. 2020:10.1111.

Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. C4591001 clinical trial group. safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603-15.

Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J Clin Med. 2021;10(7):1428.

WHO. Immunization Safety Surveillance, Guidelines for managers of immunization programmes on reporting and investigating adverse events following immunization. 2nd edn. 2013.

Kaur RJ, Dutta S, Bhardwaj P, Charan J, Dhingra S, Mitra P, et al. Adverse events reported from covid-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021:1-13.

Kadali RAK, Janagama R, Peruru S, Gajula V, Madathala RR, Chennaiahgari N, et al. Non-life-threatening adverse effects with COVID-19 mRNA-1273 vaccine: a randomized, cross-sectional study on healthcare workers with detailed self-reported symptoms. J Med Virol. 2021;93(7):4420-9.

Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021:S1473-3099(21)00224-3.

CDC COVID-19 Response Team; Food and Drug Administration. Allergic reactions including Anaphylaxis after receipt of the first dose of Pfizer-BioNtech COVID-19 vaccine- United States. Morb Mortal Wkly Rep. 2021;70:46-51.